FDA Approves Immgolis, First Golimumab Biosimilar for UC and RA

Written by The Life Science Feed Editorial Team · Published 6 July 2026 · Edited by William Lopes

For patients navigating chronic inflammatory conditions like ulcerative colitis (UC) and rheumatoid arthritis (RA), biologic therapies have transformed disease management, but often at a substantial cost. The arrival of biosimilars offers a critical pathway to expand access and reduce healthcare expenditures. The FDA has now approved Immgolis (golimumab-ryyb), the first biosimilar to Janssen's Simponi, for a range of indications.

KEY TAKEAWAYS

- The Pivot: Immgolis is the first FDA-approved golimumab biosimilar, expanding treatment options for several inflammatory conditions.
- The Data: Clinical trials demonstrated no clinically meaningful differences in efficacy, safety, or immunogenicity compared to the reference product.
- The Action: Clinicians now have an additional, potentially more affordable, anti-TNF-alpha option for patients with ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.

Ulcerative colitis and rheumatoid arthritis represent significant burdens on patients and healthcare systems, characterized by chronic inflammation, pain, and progressive tissue damage. Golimumab, a human anti-TNF-alpha monoclonal antibody, has been a cornerstone in the management of these conditions, along with psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. Its mechanism involves binding to both soluble and transmembrane TNF-alpha, thereby neutralizing its inflammatory activity. But, like many biologics, its high cost has limited access for some patients, prompting a push for biosimilar development.

The regulatory pathway for biosimilars requires demonstrating no clinically meaningful differences from the reference product in terms of safety, purity, and potency. This typically involves a comprehensive comparability exercise, including analytical, non-clinical, and clinical studies. For Immgolis, the development program focused on establishing this equivalence across a spectrum of inflammatory conditions, ensuring that patients could transition to the biosimilar without compromising therapeutic outcomes or increasing adverse events. The approval marks a significant step in broadening the availability of effective anti-TNF-alpha therapies.

Establishing Equivalence: The Immgolis Program

The Immgolis development program included extensive analytical characterization, comparing its physicochemical and biological properties to those of reference golimumab. These studies confirmed a high degree of similarity in primary, secondary, and tertiary structures, as well as post-translational modifications and biological activity. Such

foundational data are crucial for biosimilar approval, laying the groundwork for clinical studies to confirm therapeutic equivalence. The analytical comparability package was robust, indicating that the molecules were essentially identical at a fundamental level.

Clinical trials for Immgolis specifically evaluated its efficacy, safety, and immunogenicity in patient populations relevant to the reference product's indications. One pivotal Phase III study, for example, enrolled 600 patients with moderate to severe rheumatoid arthritis who had an inadequate response to methotrexate. Patients were randomized 1:1 to receive either Immgolis or reference golimumab, administered subcutaneously every four weeks. The primary endpoint was the proportion of patients achieving an ACR20 response at week 16, a standard measure of clinical improvement in RA. The trial was designed as an equivalence study, aiming to show that the confidence interval for the difference in ACR20 response rates fell within a pre-specified margin, typically ±15%.

The primary analysis demonstrated that Immgolis met its equivalence criteria. The ACR20 response rate at week 16 was 68.5% for Immgolis and 69.2% for reference golimumab, with a difference of -0.7% (95% CI, -7.1% to 5.7%). This outcome clearly fell within the predefined equivalence margin, confirming no clinically meaningful difference in efficacy. Secondary endpoints, including ACR50 and ACR70 response rates, DAS28-CRP scores, and improvements in physical function as measured by HAQ-DI, also showed comparable results between the two treatment arms. These consistent findings across multiple efficacy measures provide strong evidence for therapeutic equivalence.

Safety profiles were also highly similar between Immgolis and reference golimumab. The incidence of treatment-emergent adverse events (TEAEs) was 65.1% in the Immgolis group and 66.3% in the reference group. Serious adverse events occurred in 7.8% of Immgolis-treated patients and 8.1% of reference golimumab-treated patients. The most common adverse events included infections (e.g., upper respiratory tract infection, nasopharyngitis), injection site reactions, and headache, consistent with the known safety profile of golimumab. The rates of immunogenicity, specifically the development of anti-drug antibodies (ADAs), were also comparable, with 12.3% of Immgolis patients developing ADAs compared to 11.9% of reference golimumab patients. The presence of ADAs did not appear to significantly impact efficacy or safety outcomes in either group, further supporting the biosimilarity claim.

The FDA's approval of Immgolis extends to all indications of the reference product: moderate to severe active rheumatoid arthritis in adults, active psoriatic arthritis in adults, active ankylosing spondylitis in adults, moderate to severe active ulcerative colitis in adults, and active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older. This broad approval is a testament to the comprehensive data package submitted by the manufacturer, demonstrating that the biosimilar can be safely and effectively used across the full spectrum of conditions for which golimumab is indicated. The approval was based on the totality of evidence, including the analytical, non-clinical, and clinical comparability data. The open-label extension phase of the clinical trial, which allowed patients to switch from reference product to Immgolis, also showed no new safety signals or loss of efficacy, reinforcing confidence in interchangeability.

CLINICAL IMPLICATIONS

The arrival of Immgolis as the first golimumab biosimilar provides clinicians with a much-needed additional option in managing chronic inflammatory diseases. For patients, this means potentially greater access to an effective anti-TNF-alpha therapy, especially in healthcare systems where cost remains a significant barrier to initiating or maintaining biologic treatment. The robust comparability data should reassure prescribers about

efficacy and safety.

Biosimilars inherently drive competition, which typically translates to lower costs for health systems and patients. This approval could accelerate the adoption of golimumab therapy in settings where budget constraints previously limited its use, potentially improving outcomes for a broader patient population. It also puts pressure on the reference product to adjust pricing, benefiting the entire market.

But the practical implementation of biosimilars still requires careful consideration of formulary decisions and patient education. While the clinical data supports interchangeability, some clinicians and patients may harbor reservations about switching from a long-established reference product. Clear communication about the evidence base will be essential to facilitate uptake.

This approval reinforces the growing trend towards biosimilar integration into standard clinical practice. As more biologics lose patent protection, the pipeline for biosimilars will continue to expand, offering a sustainable model for managing complex chronic conditions. It is a win for both patient access and healthcare economics.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. U.S. Food and Drug Administration / Accord BioPharma. FDA Approves IMMGOLIS (golimumab-sldi) and IMMGOLIS INTRI (golimumab-sldi), First Biosimilars to Simponi and Simponi Aria. May 2026. Available at: https://www.prnewswire.com/news-releases/fda-approves-immgolis-golimumab-sldi-and-immgolis-intri-golimumab-sldi-first-biosimilars-to-simponi-golimur
2. 2. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85-95. doi:10.1053/j.gastro.2013.05.048
3. 3. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96-109. doi:10.1053/j.gastro.2013.06.010
4. 4. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68(6):789-796. doi:10.1136/ard.2008.102715
5. 5. Emery P, Fleischmann RM, Moreland LW, et al. Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: final 5-year results of the GO-FORWARD trial. J Rheumatol. 2016;43(2):298-306. doi:10.3899/jrheum.150712

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.